Clinical Trial Update: Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update on growth hormone for patients with poor ovarian reserve undergoing ICSI, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poor Ovarian Reserve

Drugs mentioned

• Growth Hormone (somatropin)

Snippet

Sponsor: Beni-Suef University | Conditions: Poor Ovarian Reserve | Phase 2, Phase 3 | Status: UNKNOWN